DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT03929744

CompletedPhase 1

A Study of LY3502970 in Healthy Participants

A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Healthy Subjects

Asset

Orforglipron

Oral · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

133

actual

Study population

Healthy volunteers

Key I/E criterion

•Healthy volunteers

Primary endpoint

•Serious AEs (any)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03929744
Org study ID17416
Secondary IDJ2A-MC-GZGAEli Lilly and Company

Timeline

Milestones

Study first posted2019-04-29actual
Study start2019-06-12actual
Primary completion2020-11-02actual
Study completion2020-11-02actual
Last update posted2020-11-18actual

Assets

Investigational agents

Orforglipron

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•Healthy male or females, as determined by medical history
•Have safety laboratory results within normal reference ranges

Exclusion criteria

•Have known allergies to LY3502970, glucagon-like peptide-1 (GLP-1) analogs, related compounds
•Abnormal electrocardiogram (ECG) at screening
•Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders.

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

4 endpoints
Primary/protocol endpoint

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug

Time frame:Baseline up to Day 42

Serious AEs (any)

event count, event

Secondary/protocol endpoint

Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970

Time frame:Predose up to 96 hours postdose

Cmax

concentration, descriptive

Secondary/protocol endpoint

PK: Area Under the Concentration Versus Time Curve from Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970

Time frame:Predose up to 96 hours postdose

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

PK: Time of Maximum Observed Concentration (Tmax) of LY3502970

Time frame:Predose up to 96 hours postdose

Tmax

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.